India’s Dishman To Build $113 Million Plant For Anti-Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
Dishman Pharmaceuticals said it would invest $113.1 million in facilities in a pair of Indian economic zones where it has land. The firm said in filings with the Bombay Stock Exchange it intends to begin work in each of the zones by the end of this year. Separately, Dishman said it is in the process of constructing the largest facility in Asia, dedicated to high-potency drugs such as those to treat cancer. The facility is to be built in conjunction with its existing Bavla plant in Gujarat. (Click here for more
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.